951 related articles for article (PubMed ID: 23021882)
21. Continuous apple consumption induces oral tolerance in birch-pollen-associated apple allergy.
Kopac P; Rudin M; Gentinetta T; Gerber R; Pichler Ch; Hausmann O; Schnyder B; Pichler WJ
Allergy; 2012 Feb; 67(2):280-5. PubMed ID: 22070352
[TBL] [Abstract][Full Text] [Related]
22. Sublingual immunotherapy induces IL-10-producing T regulatory cells, allergen-specific T-cell tolerance, and immune deviation.
Bohle B; Kinaciyan T; Gerstmayr M; Radakovics A; Jahn-Schmid B; Ebner C
J Allergy Clin Immunol; 2007 Sep; 120(3):707-13. PubMed ID: 17681368
[TBL] [Abstract][Full Text] [Related]
23. Immunotherapy with a modified birch pollen extract in allergic rhinoconjunctivitis: clinical and immunological effects.
Ceuppens JL; Bullens D; Kleinjans H; van der Werf J;
Clin Exp Allergy; 2009 Dec; 39(12):1903-9. PubMed ID: 20085600
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of recombinant and native timothy pollen (rPhl p 1, 2, 5, 6, 7, 11, 12 and nPhl p 4)- specific IgG4 antibodies induced by subcutaneous immunotherapy with timothy pollen extract in allergic patients.
Rossi RE; Monasterolo G
Int Arch Allergy Immunol; 2004 Sep; 135(1):44-53. PubMed ID: 15286445
[TBL] [Abstract][Full Text] [Related]
25. Grass tablet sublingual immunotherapy downregulates the TH2 cytokine response followed by regulatory T-cell generation.
Suárez-Fueyo A; Ramos T; Galán A; Jimeno L; Wurtzen PA; Marin A; de Frutos C; Blanco C; Carrera AC; Barber D; Varona R
J Allergy Clin Immunol; 2014 Jan; 133(1):130-8.e1-2. PubMed ID: 24290282
[TBL] [Abstract][Full Text] [Related]
26. Efficacy of recombinant birch pollen vaccine for the treatment of birch-allergic rhinoconjunctivitis.
Pauli G; Larsen TH; Rak S; Horak F; Pastorello E; Valenta R; Purohit A; Arvidsson M; Kavina A; Schroeder JW; Mothes N; Spitzauer S; Montagut A; Galvain S; Melac M; André C; Poulsen LK; Malling HJ
J Allergy Clin Immunol; 2008 Nov; 122(5):951-60. PubMed ID: 19000581
[TBL] [Abstract][Full Text] [Related]
27. Detection of specific IgE antibodies in sera of Japanese birch-allergic patients using recombinant allergens Bet v 1, Bet v 2 and Bet v 4.
Shirasaki H; Yamamoto T; Koyanagi Y; Watanabe N; Himi T
Allergol Int; 2008 Mar; 57(1):93-6. PubMed ID: 18209509
[TBL] [Abstract][Full Text] [Related]
28. An assay that may predict the development of IgG enhancing allergen-specific IgE binding during birch immunotherapy.
Selb R; Eckl-Dorna J; Vrtala S; Valenta R; Niederberger V
Allergy; 2013 Sep; 68(9):1199-202. PubMed ID: 23998344
[TBL] [Abstract][Full Text] [Related]
29. A hypoallergenic variant of the major birch pollen allergen shows distinct characteristics in antigen processing and T-cell activation.
Kitzmüller C; Wallner M; Deifl S; Mutschlechner S; Walterskirchen C; Zlabinger GJ; Ferreira F; Bohle B
Allergy; 2012 Nov; 67(11):1375-82. PubMed ID: 22973879
[TBL] [Abstract][Full Text] [Related]
30. Is immunotherapy-induced birch-pollen-specific IgG4 a marker for decreased allergen-specific sensitivity?
Bodtger U; Ejrnaes AM; Hummelshoj L; Jacobi HH; Poulsen LK; Svenson M
Int Arch Allergy Immunol; 2005 Apr; 136(4):340-6. PubMed ID: 15741732
[TBL] [Abstract][Full Text] [Related]
31. Accelerated Up-Dosing of Subcutaneous Immunotherapy with a Registered Allergoid Birch Pollen Preparation.
Buczyłko K; van der Werf JF; Boot D; van Ree R
Int Arch Allergy Immunol; 2017; 172(3):183-186. PubMed ID: 28380494
[TBL] [Abstract][Full Text] [Related]
32. Mapping of conformational IgE epitopes with peptide-specific monoclonal antibodies reveals simultaneous binding of different IgE antibodies to a surface patch on the major birch pollen allergen, Bet v 1.
Gieras A; Cejka P; Blatt K; Focke-Tejkl M; Linhart B; Flicker S; Stoecklinger A; Marth K; Drescher A; Thalhamer J; Valent P; Majdic O; Valenta R
J Immunol; 2011 May; 186(9):5333-44. PubMed ID: 21451110
[TBL] [Abstract][Full Text] [Related]
33. The major birch pollen allergen Bet v 1 induces different responses in dendritic cells of birch pollen allergic and healthy individuals.
Smole U; Radauer C; Lengger N; Svoboda M; Rigby N; Bublin M; Gaier S; Hoffmann-Sommergruber K; Jensen-Jarolim E; Mechtcheriakova D; Breiteneder H
PLoS One; 2015; 10(1):e0117904. PubMed ID: 25635684
[TBL] [Abstract][Full Text] [Related]
34. [IgE and IgG antibody response in patients with type I allergy to birch pollen].
Rumpold H; Jarolim E; Bonitz W; Tejkl M; Breitenbach M; Scheiner O; Kraft D
Wien Klin Wochenschr; 1989 Feb; 101(3):107-10. PubMed ID: 2922932
[TBL] [Abstract][Full Text] [Related]
35. Innate and lymphocytic response of birch-allergic patients before and after sublingual immunotherapy.
Guida G; Boita M; Scirelli T; Bommarito L; Heffler E; Badiu I; Bellone G; Mietta S; Mistrello G; Rolla G
Allergy Asthma Proc; 2012; 33(5):411-5. PubMed ID: 22762741
[TBL] [Abstract][Full Text] [Related]
36. Bet v 1-specific IgA increases during the pollen season but not after a single allergen challenge in children with birch pollen-induced intermittent allergic rhinitis.
Keen C; Johansson S; Reinholdt J; Benson M; Wennergren G
Pediatr Allergy Immunol; 2005 May; 16(3):209-16. PubMed ID: 15853949
[TBL] [Abstract][Full Text] [Related]
37. Immune regulation by CD4+CD25+ T cells and interleukin-10 in birch pollen-allergic patients and non-allergic controls.
Thunberg S; Akdis M; Akdis CA; Grönneberg R; Malmström V; Trollmo C; van Hage M; Gafvelin G
Clin Exp Allergy; 2007 Aug; 37(8):1127-36. PubMed ID: 17651141
[TBL] [Abstract][Full Text] [Related]
38. Three-year follow-up study of allergen-induced in vitro cytokine and signalling lymphocytic activation molecule mRNA responses in peripheral blood mononuclear cells of allergic rhinitis patients undergoing specific immunotherapy.
Nieminen K; Laaksonen K; Savolainen J
Int Arch Allergy Immunol; 2009; 150(4):370-6. PubMed ID: 19571569
[TBL] [Abstract][Full Text] [Related]
39. Intralymphatic allergen-specific immunotherapy: an effective and safe alternative treatment route for pollen-induced allergic rhinitis.
Hylander T; Latif L; Petersson-Westin U; Cardell LO
J Allergy Clin Immunol; 2013 Feb; 131(2):412-20. PubMed ID: 23374268
[TBL] [Abstract][Full Text] [Related]
40. Recombinant allergen-based monitoring of antibody responses during injection grass pollen immunotherapy and after 5 years of discontinuation.
Gadermaier E; Staikuniene J; Scheiblhofer S; Thalhamer J; Kundi M; Westritschnig K; Swoboda I; Flicker S; Valenta R
Allergy; 2011 Sep; 66(9):1174-82. PubMed ID: 21480924
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
